Showing 3971-3980 of 5333 results for "".
- New from Lumenis: Meet the Stellar M22 Platformhttps://practicaldermatology.com/news/new-from-lumenis-meet-the-stellar-m22-platform/2460300/Lumenis Ltd. is launching the Stellar M22, a multi-application platform that builds on the heritage of the M22 by adding even more bells and whistles. The new Stellar M22 is now available in the USA and Europ
- FDA Accepts NDA for Almirall's AK Drug Tirbanibulinhttps://practicaldermatology.com/news/fda-accepts-nda-for-almiralls-ak-drug-tirbanibulin/2460299/The FDA has reviewed and accepted the New Drug Application (NDA) from Almirall, SA for tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis (AK). The FDA also communicated that it is not currently planning on holding an advisory committee to discuss the application. <
- Study: DermTech’s Non-Invasive Gene Expression Testing Improves Early Melanoma Detectionhttps://practicaldermatology.com/news/study-dermtechs-non-invasive-gene-expression-testing-improves-early-melanoma-detection/2460297/A large registry study confirms that DermTech Pigmented Lesion Assay can reduce unnecessary biopsies by up to 90 percent, lower healthcare costs, and rule out melanoma. “The DermTech PLA helps clinicians employ precision dermatology and harness genomics technology to detect malign
- Galderma Rolls Out New Consumer-Facing Rewards App, Plus Morehttps://practicaldermatology.com/news/galderma-rolls-out-new-consumer-facing-rewards-app-plus-more-1/2460296/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- First Patient Enrolled in Avita Medical’s Pivotal Study Evaluating Recell System for Soft Tissue Reconstructionhttps://practicaldermatology.com/news/first-patient-enrolled-in-avita-medicals-pivotal-study-evaluating-recell-system-for-soft-tissue-reconstruction/2460294/Avita Medical Limited enrolled the first patient in a study evaluating the Recell System for Soft Tissue Reconstruction at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. The prospective multi-center trial of at least 65 patients will compare the clinical per
- Sciton Names New CEOhttps://practicaldermatology.com/news/sciton-names-new-ceo/2460292/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently operations in our World Head
- Dermatologists React to Threat of Coronavirus Pandemichttps://practicaldermatology.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic/2460291/Reports about COVID-19 are causing many dermatologists to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a “public health emerge
- Aesthetics Biomedical Taps Molly Sims As New SoME Skincare Brand Ambassadorhttps://practicaldermatology.com/news/aesthetics-biomedical-taps-molly-sims-as-new-some-skincare-brand-ambassador/2460290/Molly Sims is Brand Ambassador for Aesthetics Biomedical’s SoME Skincare That's All You, a patented personalized Platelet Rich Plasma (PRP) skincare for at-home use. SoME That's All You is com
- Business News: Lilly, Dermira Acquisition Completehttps://practicaldermatology.com/news/business-news-lilly-dermira-acquisition-complete/2460287/Eli Lilly and Company has completed its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 that is being evaluated in a Phase 3 clinical development
- Sun Pharma Survey: Impact of Psoriasis on Patients is Extensivehttps://practicaldermatology.com/news/sun-pharma-survey-impact-of-psoriasis-on-patients-is-extensive/2460284/The impact of moderate-to-severe plaque psoriasis on social and personal interactions can be extensive, results of a new survey from Sun Pharma confirm. In fact, 44 percent of respondents said that they often or sometimes feel humiliated by the appearance of psoriasis. More than a quarter (28 per